Eli Casdin - Jun 14, 2023 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director
Signature
/s/ Eli Casdin by Agnieszka Gallagher, Attorney-in-Fact
Stock symbol
LAB
Transactions as of
Jun 14, 2023
Transactions value $
$0
Form type
4
Date filed
6/16/2023, 08:49 PM
Previous filing
May 19, 2023
Next filing
Jul 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +26.4K +56.4% $0.00 73.1K Jun 14, 2023 Direct F1
holding LAB Common Stock 1.2M Jun 14, 2023 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Stock Option (Right to Buy) Award $0 +35.4K $0.00 35.4K Jun 14, 2023 Common Stock 35.4K $2.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.
F2 The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F3 The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney